The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Use of ciprofloxacin in patients undergoing transurethral prostatic surgery

På svenska

Author

Summary, in English

The efficacy of a short (Group I) and a prolonged (Group II) course with ciprofloxacin was assessed in patients undergoing transurethral prostatic resection and compared with that of controls without antibiotic (Group III). Both regimens significantly reduced the frequency of post-operative bacteriuria (p less than 0.01) and of severe infectious complications (p = 0.004) compared to the controls. Both regimens were equally effective in preventing peri-operative and post-operative acquisition of bacteriuria in patients without bacteriuria at surgery. In patients with bacteriuria before surgery, bacteriuria was found post-operatively in 35% in Group I and in 9% in Group II (p = 0.012), but in 82% of the patients in Group III. Ciprofloxacin inhibited all but 7 of 176 bacterial strains at an MIC of less than or equal to 1 microgram/ml. Given orally, ciprofloxacin is a valuable alternative antimicrobial for use in conjunction with transurethral prostatic resection. A short course is sufficient for prophylaxis, and adequate therapy is achieved with a prolonged regimen.

Publishing year

1989

Language

English

Pages

104-107

Publication/Series

Scandinavian Journal of Infectious Diseases. Supplementum

Volume

60

Document type

Journal article

Publisher

Scandinavian University Press

Topic

  • Clinical Medicine
  • Microbiology in the medical area
  • Cancer and Oncology
  • Urology and Nephrology

Status

Published

Research group

  • Clinical Microbiology, Malmö
  • Urological cancer, Malmö

ISBN/ISSN/Other

  • ISSN: 0300-8878